Literature DB >> 24384461

Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Jean-Philip Truman1, Mónica García-Barros2, Lina M Obeid3, Yusuf A Hannun4.   

Abstract

Traditional methods of cancer treatment are limited in their efficacy due to both inherent and acquired factors. Many different studies have shown that the generation of ceramide in response to cytotoxic therapy is generally an important step leading to cell death. Cancer cells employ different methods to both limit ceramide generation and to remove ceramide in order to become resistant to treatment. Furthermore, sphingosine kinase activity, which phosphorylates sphingosine the product of ceramide hydrolysis, has been linked to multidrug resistance, and can act as a strong survival factor. This review will examine several of the most frequently used cancer therapies and their effect on both ceramide generation and the mechanisms employed to remove it. The development and use of inhibitors of sphingosine kinase will be focused upon as an example of how targeting sphingolipid metabolism may provide an effective means to improve treatment response rates and reduce associated treatment toxicity. This article is part of a Special Issue entitled Tools to study lipid functions.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Ceramide; Chemoresistance; Inhibitor; Sphingosine kinase; Sphingosine-1-phosphate

Mesh:

Substances:

Year:  2013        PMID: 24384461      PMCID: PMC4221100          DOI: 10.1016/j.bbalip.2013.12.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  265 in total

1.  The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function.

Authors:  Lilly Chai; Rajashree P McLaren; Ann Byrne; Wei-Lien Chuang; Yinyin Huang; Michael R Dufault; Joshua Pacheco; Shruti Madhiwalla; Xiaokui Zhang; Mindy Zhang; Beverly A Teicher; Kara Carter; Seng H Cheng; John P Leonard; Yibin Xiang; Michael Vasconcelles; Mark A Goldberg; Diane P Copeland; Katherine W Klinger; James Lillie; Stephen L Madden; Yide A Jiang
Journal:  Int J Oncol       Date:  2010-12-24       Impact factor: 5.650

Review 2.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

3.  Modulation of Akt kinase activity by binding to Hsp90.

Authors:  S Sato; N Fujita; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Long-term infertility and dominant lethal mutations in male mice treated with adriamycin.

Authors:  M L Meistrich; L S Goldstein; A J Wyrobek
Journal:  Mutat Res       Date:  1985-10       Impact factor: 2.433

5.  Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase.

Authors:  W C Liao; A Haimovitz-Friedman; R S Persaud; M McLoughlin; D Ehleiter; N Zhang; M Gatei; M Lavin; R Kolesnick; Z Fuks
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

6.  The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system.

Authors:  S T Eichhorst; S Müerköster; M A Weigand; P H Krammer
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

7.  Role of ceramide during cisplatin-induced apoptosis in C6 glioma cells.

Authors:  S Noda; S Yoshimura; M Sawada; T Naganawa; T Iwama; S Nakashima; N Sakai
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

8.  Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide.

Authors:  D Myrick; D Blackinton; J Klostergaard; N Kouttab; A Maizel; H Wanebo; S Mehta
Journal:  Leuk Res       Date:  1999-06       Impact factor: 3.156

9.  Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent.

Authors:  Kai Liu; Tai L Guo; Nitai C Hait; Jeremy Allegood; Hardik I Parikh; Wenfang Xu; Glen E Kellogg; Steven Grant; Sarah Spiegel; Shijun Zhang
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

10.  Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway.

Authors:  Youssef H Zeidan; Russell W Jenkins; Yusuf A Hannun
Journal:  J Cell Biol       Date:  2008-04-21       Impact factor: 10.539

View more
  49 in total

1.  Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study.

Authors:  Jinli Lv; Bo Zhu; Liang Zhang; Qichao Xie; Wenlei Zhuo
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Authors:  Keith R Stayrook; Justin K Mack; Donna Cerabona; Daniel F Edwards; Hai H Bui; Maria Niewolna; Pierrick Gj Fournier; Khalid S Mohammad; David L Waning; Theresa A Guise
Journal:  Bonekey Rep       Date:  2015-07-08

Review 3.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

4.  A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

Authors:  Carolyn D Britten; Elizabeth Garrett-Mayer; Steven H Chin; Keisuke Shirai; Besim Ogretmen; Tricia A Bentz; Alan Brisendine; Kate Anderton; Susan L Cusack; Lynn W Maines; Yan Zhuang; Charles D Smith; Melanie B Thomas
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

5.  Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.

Authors:  Samy A F Morad; Traci S Davis; Matthew R MacDougall; Su-Fern Tan; David J Feith; Dhimant H Desai; Shantu G Amin; Mark Kester; Thomas P Loughran; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2017-02-09       Impact factor: 5.858

Review 6.  Ceramide induced mitophagy and tumor suppression.

Authors:  Mohammed Dany; Besim Ogretmen
Journal:  Biochim Biophys Acta       Date:  2015-01-26

7.  The possible role of Sirtuins and microRNAs in hepatocellular carcinoma therapy.

Authors:  Hedyieh Karbasforooshan; A Wallace Hayes; Nooshin Mohammadzadeh; Mohammad Reza Zirak; Gholamreza Karimi
Journal:  Cell Cycle       Date:  2020-11-09       Impact factor: 4.534

8.  An endoplasmic reticulum stress-initiated sphingolipid metabolite, ceramide-1-phosphate, regulates epithelial innate immunity by stimulating β-defensin production.

Authors:  Young-Il Kim; Kyungho Park; Jong Youl Kim; Ho Seong Seo; Kyong-Oh Shin; Yong-Moon Lee; Walter M Holleran; Peter M Elias; Yoshikazu Uchida
Journal:  Mol Cell Biol       Date:  2014-10-13       Impact factor: 4.272

9.  Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Authors:  Samy A F Morad; Su-Fern Tan; David J Feith; Mark Kester; David F Claxton; Thomas P Loughran; Brian M Barth; Todd E Fox; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-03-10

10.  LAPTM4B facilitates late endosomal ceramide export to control cell death pathways.

Authors:  Tomas Blom; Shiqian Li; Andrea Dichlberger; Nils Bäck; Young Ah Kim; Ursula Loizides-Mangold; Howard Riezman; Robert Bittman; Elina Ikonen
Journal:  Nat Chem Biol       Date:  2015-08-17       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.